- Price
- $183.99
- Day
- +1.28%
- Mkt Cap
- $11.81B
- 52W Range
- $101.00 – $247.49
- Volume
- 449.4K
- Beta
- 0.83
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
Investors need to pay close attention to DVA stock based on the movements in the options market lately.
Read full article
DaVita HealthCare (DVA) reported earnings 30 days ago. What's next for the stock?
Read full article
An aging population and growing telehealth and AI adoption support the Zacks Medical - Outpatient and Home Healthcare industry. DVA, LFST, OPCH and AVAH stand to benefit.
Read full article
In fact, it's a healthcare company. It is a strong player in its chosen niche.
Read full article
SHANGHAI, Aug. 26, 2026 /PRNewswire/ -- Alebund Pharmaceuticals (Jiangsu) Limited ("Alebund" or the "Company"; stock code: 09637.HK), a renal-focused biopharmaceutical company, today announced its unaudited consolidated interim results for the six months ended June 30, 2026 (the "Reporting Period"). During the Reporting Period and up to the date of the interim results announcement, the Company made significant progress on four fronts: clinical development, external collaborations, commercialization in China, and the capital markets.
Read full article
DaVita expands its Humana partnership to earlier-stage kidney disease, bringing value-based care to over 10,000 Medicare Advantage members.
Read full article
BlackRock Inc. purchased a new position in DaVita Inc. (NYSE: DVA) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 2,460,987 shares of the company's stock, valued at approximately $547,520,000. BlackRock Inc. owned approximately 3.86% of DaVita as of its most recent SEC filing.
Read full article
Bank of New York Mellon Corp purchased a new stake in DaVita Inc. (NYSE: DVA) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 454,545 shares of the company's stock, valued at approximately $101,127,000. Bank of New York Mellon Corp owned approximately
Read full article
More than 10,000 members will get added support aimed at delaying or preventing dialysis and reducing hospitalizations DENVER, Aug. 25, 2026 /PRNewswire/ -- DaVita today announced a new value-based care agreement to deliver comprehensive, coordinated care to Humana Medicare Advantage members with chronic kidney disease (CKD) stages 3B–5. Launched July 1, this partnership builds on the organizations' long-standing collaboration in end stage kidney disease and expands earlier into the disease journey, when intervention can have the greatest impact.
Read full article